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In this issue of EJEP, Kato et al. describe their ge-
notype–phenotype analysis in a small study group
comprising both Caucasian people and African–
Americans. In their study group the most frequent
allele of the polymorphism in the promoter region of
the IGF-I gene contains 18 CA repeats in both ethnic
groups and no homozygote carriers of the 19 CA
repeat were found. In Whites the frequency of the 19
CA repeat was significantly higher compared to Af-
rican Americans. No relation was found between the
number of CA repeats and serum IGF-I levels among
all the subjects combined or in the white or black
subgroups separately. A positive relation was found
between IGF-I levels and height and cigarette
smoking, and as expected age tended to be inversely
associated with serum IGF-I.
Several points need to be addressed. One issue is
the allele that is most frequently present in the study
population. The IGF-I gene, which is located on
chromosome 12q, contains in the promoter region a
micro-satellite comprising a variable length of a
CA repeat sequence. Length of the repeat sequence
ranges from 10 to 24, with the most frequent allele
containing 19 CA repeats in six previous studies all
involving Caucasian people [1–6]. In a previous study
in African–Americans only the most frequent allele
contained 18 CA repeats [7]. This suggests that dur-
ing evolution there has been a shift towards longer
alleles.
Kato et al. observe the 18 CA repeat allele as most
frequent in both Caucasians and African–Americans
and explain their different results by the small num-
ber of subjects studied (total study group 113 subjects
consisting of 57 African–Americans and 56 Cauca-
sian people), by population admixture and/or by the
use of a different genotyping method. Studies in
which more than 450 healthy subjects are studied
regarding the IGF-I promoter polymorphism found
an allele frequency of the 19 CA repeat allele between
55.5 and 88%, with a genotype frequency for ho-
mozygous carriers between 37.3 and 46.8% [3–7]. In
large studies a more narrow range in frequency of
homozygous carriers of the wild type allele is ob-
served than in small studies. Small sized studies can
therefore, regardless of the study design, be expected
to deviate from the population characteristics.
Serum IGF-I levels differ between ethnic groups, so
it is not strange to expect differences in IGF-I allele
frequencies between ethnic groups. A shift towards
longer alleles during evolution is suggested from the
study from Kato et al. as well as that from Takacs
et al. In this regard the observed shorter allele in
African–Americans is in accordance that they repre-
sent an older race than Caucasians [7]. The fact that
in Whites in the study from Kato also this allele is
found to be the most frequent implies indirectly the
involvement of older US populations. Hardy–Wein-
berg equilibrium, tested by v2 statistics was not re-
jected, but this could be due to chance because of the
small study group.
Automated DNA sequencing of all samples was
done in order to determine the length of CA repeats.
Methods relying on gel electrophoresis may not be
sensitive enough to distinguish heterozygous alleles
with differences of one repeat. However, more recent
studies using an autosequencer described the 19 CA
repeat allele in Caucasian people as the most frequent
[3, 4]. Also determination of the IGF-I genotypes
should be checked by at least two different investi-
gators, because the software sometimes misclassifies
homozygote carriers if the size of the peak-height of
background noise is higher than the peak-height of
the PCR product.
Another reason for the different outcome could be
the selection of the controls. The controls in the study
by Kato et al. were selected from an on-going hos-
pital-based case–control study for prostate and breast
cancer. All controls participated in the screening
program for prostate cancer or visited the Breast
Clinic but were not found to have malignant lesions.
People participating in the screening programme or
visiting the Breast Clinic may have complaints which
could be related to prostate or breast cancer. Because
the controls do not represent a population-based
study group, differences in allele frequencies could
have occurred.
Another outcome from this selection is a clear de-
viation of the observed mean IGF-I levels from
normal values. The highest mean is found in the
youngest age group (six subjects in the age range
from 22 to 39 years of age), and is 146.6 ng/ml
(=146.6 ug/L) where the normal reference range in
this age group is 114–492 ug/L [8]. The other IGF-I
levels are also lower than expected for their age. Low
serum IGF-I levels are thought to be a consequence
of growth hormone deficiency, malnutrition, liver
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dysfunction or ageing, but also certain diseases reflect
low serum IGF-I levels [9, 10].
Several studies examined the relationship between
serum IGF-I levels and osteoporosis and cardiovas-
cular diseases [1, 11, 12]. Serum IGF-I levels seem to
correlate well with bone mineral density and could
therefore be related to osteoporosis [1, 13]. In car-
diovascular diseases, low serum IGF-I after acute
myocardial infarction has been associated with bad
survival [11]. The question remains whether the sub-
jects studied by Kato et al. really represent a healthy
population. Another problem is that different types
of specimen differ in their mean IGF-I levels. Com-
mercially available kits from Medgenix and DSL
state that measurements in plasma result in lower
IGF-I levels compared to those in serum. Also a
significantly higher mean IGF-I level was observed in
serum compared to EDTA plasma and heparin
plasma (157.5 ± 45.6 vs. 137.8 ± 42.5 and
141.3 ± 39.3; p < 0.001) [14]. The reason for the
relatively low IGF-I levels in the present selected
study group could therefore be diverse. However,
we do not have enough information to find out its
cause.
Kato et al. found no consistent trend in plasma
IGF-I levels by age and no relation was observed
between IGF-I alleles and IGF-I levels. Serum total
IGF-I levels have been measured in healthy infants,
children, adolescents and adults [15–18]. Levels in-
crease fast during the first year of life, followed by a
linear increase from early childhood into adolescence
[15, 16]. During puberty a steep increase is seen to
approximately 500 ug/L and after reaching it’s maxi-
mum level, IGF-I levels decline with age toward
prepubertal levels in adults (approximately 300 ug/
L), followed by a further slow decrease until 70 years
of age [15–17]. Lack of overall association between
age and IGF-I levels in the present study could also
be due to the small sample size and a wide age-range
resulting in low numbers of subjects present in the age
categories.
Several previous studies have been directed at the
potential functionality of this polymorphism. Results
so far have been conflicting. Vaessen et al. observed a
higher serum total IGF-I level in homozygote carriers
of the 19 CA repeat allele compared to non-carriers
of this most frequent allele [4]. Frayling et al. de-
scribed the opposite effect: low serum IGF-I levels
were observed in homozygote carriers of the wild type
allele compared to non-carriers of the 19 CA repeat
allele [3]. Other studies did not find a relation between
this polymorphism and IGF-I levels [5].
In conclusion, ethnicity, size of the study group
and the genotyping method used by Kato et al. might
have blurred the precise association between the
polymorphism studied and its functional conse-
quences.
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